title: [Botulinum toxin treatment in children].
abstract: Botulinum toxin type A treatments in children were started nearly 20 years ago. The first and still most common indication is spastic equinus gait in cerebral palsy, but other indications have emerged, such as idiopathic toe-walking, peri- and post-operative pain, drooling and idiopathic congenital torticollis. The official indication for botulinum toxin treatment is spastic equinus gait in children over 2 years of age. Botulinum toxin is known as the most potent toxin. However, it has proved to be safe and well tolerated among paediatric patients. Adverse events are infrequent, mostly bruising and limited, temporary muscle weakness. With higher doses the risk for generalized adverse events increases.
authors.affiliation: Kanta-Hämeen keskussairaalan lastenneurologinen yksikkö, TAYS:n lastenneurologinen yksikkö.
authors.forename: Heli
authors.initials: H
authors.lastname: Sätilä
authors.forename: Vesa
authors.initials: V
authors.lastname: Vähäsarja
authors.forename: Pasi
authors.initials: P
authors.lastname: Paavilainen
mesh_terms: D019274:Botulinum Toxins, Type A / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002547:Cerebral Palsy / Q000188:drug therapy*; D002648:Child; D004863:Equinus Deformity / Q000188:drug therapy*; D020233:Gait Disorders, Neurologic / Q000188:drug therapy*; D006801:Humans; D009465:Neuromuscular Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D010149:Postoperative Pain / Q000188:drug therapy*; D012798:Sialorrhea / Q000188:drug therapy*; D014103:Torticollis / Q000151:congenital* / Q000188:drug therapy
chemical_list: D009465:Neuromuscular Agents; D019274:Botulinum Toxins, Type A